Sun Pharmaceutical Share News - Latest Updates, Live News & More

Latest news about Sun Pharmaceutical

Sun Pharmaceutical Industries Executes ₹278.87 Crore Block Trade on NSE 2 days ago

Sun Pharmaceutical Industries Limited completed a major block trade on NSE worth ₹278.87 crores involving 1,734,892 shares at ₹1607.40 per share. The transaction represents significant institutional trading activity in the pharmaceutical major's equity.

China Halts Sales of Sun Pharma's Dementia Drug Following Remote Inspection Issues 3 days ago

Sun Pharma Receives Approval for Generic Semaglutide Injection NovelTreat in India 7 days ago

Jefferies Maintains 'Buy' Rating on Sun Pharma with ₹2,100 Target Price 9 days ago

Sun Pharmaceutical Industries Schedules Board Meeting for Q3FY26 Results and Interim Dividend Consideration 10 days ago

More news about Sun Pharmaceutical

20Jan 26

Sun Pharmaceutical Industries Executes ₹20.56 Crore Block Trade on NSE

Sun Pharmaceutical Industries Ltd. completed a block trade worth ₹20.56 crores on NSE, involving approximately 125,250 shares at ₹1,641.20 per share. The transaction represents significant institutional activity in the pharmaceutical company's stock through the block trade mechanism.

19Jan 26

Sun Pharmaceutical Industries Denies $10 Billion Organon Acquisition Rumors

Sun Pharmaceutical Industries has officially denied rumors of a $10 billion acquisition of Organon, stating the information is speculative. The company clarified that no significant event requiring disclosure has occurred and emphasized its commitment to proper regulatory compliance and transparency with stakeholders.

19Jan 26

Sun Pharma Officially Denies $10 Billion Organon Acquisition Speculation

Sun Pharmaceutical Industries has officially denied media speculation regarding a potential $10 billion acquisition of US-based Organon through a formal BSE regulatory filing. The company stated the reports are speculative in nature with no material event requiring disclosure under Regulation 30, while reaffirming its commitment to maintaining highest governance standards and transparent communication with stakeholders.

16Jan 26

Sun Pharma Launches Unloxcyt™ for Advanced Cutaneous Squamous Cell Carcinoma Treatment

Sun Pharmaceutical has launched Unloxcyt™ (Cosibelimab-IPDL) for treating advanced cutaneous squamous cell carcinoma. This new oncology product expands the company's therapeutic portfolio and provides healthcare professionals with an additional treatment option for patients with this form of skin cancer, demonstrating Sun Pharma's continued commitment to addressing unmet medical needs in cancer care.

14Jan 26

LIC Increases Shareholding in Sun Pharmaceutical Industries to 5.004%

Life Insurance Corporation of India has increased its shareholding in Sun Pharmaceutical Industries Limited to 5.004% by acquiring 2,02,500 shares through market purchase on January 13, 2026. The acquisition took LIC's total holding to 12,00,79,148 shares from 11,98,76,648 shares, crossing the 5% threshold that requires mandatory disclosure under SEBI regulations. The disclosure was made under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, with Sun Pharmaceutical's total equity capital remaining unchanged at 2,39,93,34,970 shares.

28Dec 25

GLP-1 Obesity Treatment Drugs To Be New Growth Engine For Indian Pharma Industry: Sun Pharma MD

Sun Pharmaceutical's Managing Director Kirti Ganorkar identifies obesity and diabetes treatment drugs, particularly GLP-1 treatments, as a significant growth opportunity for India's pharmaceutical sector. The industry aims to transform from a generic drug manufacturing hub to a major player in the global weight management industry. Dr Reddy's Laboratories Chairman Satish Reddy emphasizes the need for accessible risk capital to elevate India's pharmaceutical industry to a global innovation hub. Icra projects 9-11% overall revenue growth for Indian pharmaceutical companies, with varying growth rates across different markets.

26Dec 25

Sun Pharma targets mid-high single digit revenue growth in FY26, focuses on R&D investments

Sun Pharmaceutical Industries targets mid to high single-digit consolidated revenue growth for FY26 while continuing R&D investments totaling ₹320 billion cumulatively. The company faces US policy challenges with proposed CMS pricing models that could impact its branded pharmaceuticals business. Strong Q2 performance showed net profit of ₹31.18 billion and revenue growth of 8.6% to ₹144.05 billion.

25Dec 25

Sun Pharma Unit Recalls Over 17,000 Units Of Antifungal Shampoo In US Due To Manufacturing Issues

Taro Pharmaceutical Industries, a subsidiary of Sun Pharmaceutical Industries, has recalled 17,664 units of Ciclopirox Shampoo in the United States. The recall, initiated on December 9, is due to failed impurity/degradation specifications. The FDA classified it as a Class II recall, indicating potential temporary or medically reversible health consequences. Ciclopirox Shampoo is used to treat seborrheic dermatitis, a skin condition causing dry, flaky, and itchy skin.

18Dec 25

Sun Pharma's Baska Facility Receives OAI Status After FDA Inspection

Sun Pharmaceutical Industries' Baska manufacturing facility has been classified as Official Action Indicated (OAI) following a US FDA inspection conducted from September 8-19. Despite this classification, the facility continues to manufacture and supply approved products to the US market. Sun Pharma has committed to working with the FDA to address the issues and achieve full compliance.

10Dec 25

Sun Pharma Strategically Limits Semaglutide Sales, Focuses on Patent-Free Markets

Sun Pharmaceutical Industries has adopted a cautious approach to semaglutide sales, exporting only to countries where Novo Nordisk lacks patents while suspending domestic sales until securing patent protection. This strategy reflects the company's commitment to legal compliance and intellectual property rights in the competitive pharmaceutical sector.

17Nov 25

AstraZeneca and Sun Pharma Join Forces to Expand Hyperkalemia Treatment in India

AstraZeneca Pharma India Limited and Sun Pharmaceutical Industries Limited have formed a strategic partnership to distribute Sodium Zirconium Cyclosilicate (SZC), an innovative Hyperkalemia treatment, across India. AstraZeneca will market the drug as Lokelma®, while Sun Pharma will use the brand name Gimliand®. The collaboration aims to leverage Sun Pharma's extensive distribution network to improve access to this crucial treatment for patients with chronic kidney disease and heart failure. Hyperkalemia affects up to 50% of CKD patients and 42% of chronic HF patients in India, with an associated mortality rate of 22.20%.

12Nov 25

Sun Pharma: Mixed Results for Fibromun Cancer Drug Trial and Positive Data for Obesity Drug Utreglutide

Sun Pharmaceutical Industries and Philogen S.p.A. announced mixed Phase III results for Fibromun in advanced soft tissue sarcoma. The FIBROSARC trial missed its primary endpoint but showed favorable trends in progression-free survival, objective response rate, and overall survival. Philogen plans to discuss results with regulators and initiate a new Phase III trial. Sun Pharma also presented positive clinical data for its obesity drug utreglutide (GLO034), demonstrating significant weight loss and metabolic improvements in multiple studies.

10Nov 25

Sun Pharma Reports Strong Q2 Performance with 8.6% Revenue Growth

Sun Pharmaceutical Industries posted robust Q2 FY24 results with revenue up 8.60% to ₹14,405.20 crore and net profit rising 2.60% to ₹3,118.00 crore. The global specialty business grew 16% YoY to $333 million, while domestic formulations revenue increased 11% to ₹4,734.80 crore. Operating profit rose 14.90% with margins expanding 170 bps to 31.30%. US generics faced challenges due to competition and declining Revlimid sales. R&D spending was ₹782.70 crore. The company plans to launch Unloxcyt for skin cancer in H2 FY26 and Leqselvi for alopecia areata, and enter the GLP-1 segment in India with Semaglutide.

05Nov 25

Sun Pharma Considers U.S. Manufacturing Expansion Amid Tariff Concerns and Strong Q2 Performance

Sun Pharmaceutical Industries is exploring expansion of its U.S. manufacturing operations following new tariffs on branded and patented medicines. The company reported robust Q2 results with sales of ₹144,052.00 million, up 8.60% YoY, and net profit of ₹31,180.00 million, up 2.60%. Global Innovative Medicines sales grew 16.40% to $333.00 million, surpassing Generics sales in the U.S. for the first time. Sun Pharma maintains its leading position in India with an 8.30% market share and continues to invest in R&D, with six novel entities in clinical stages.

05Nov 25

Sun Pharma Reports Robust Q2 Results with 8.86% Revenue Growth and Improved Profitability

Sun Pharmaceutical Industries Ltd announced its Q2 FY2026 financial results, showing robust performance. The company's consolidated revenue increased by 8.86% to ₹14,478.00 crore. Net profit rose by 2.57% to ₹3,118.00 crore. EBITDA grew by 14.90% to ₹4,527.00 crore, with the EBITDA margin expanding by 167 basis points to 31.27%. These results demonstrate Sun Pharma's strong market position, effective business strategies, and improved operational efficiency in the pharmaceutical industry.

04Nov 25

Sun Pharma Q2 Preview: Moderate Growth Expected Amid Specialty Business Expansion

Sun Pharmaceutical Industries Ltd is set to release its Q2 FY23-24 earnings report. Analysts project a 7% year-on-year revenue increase but only 2% growth in profit after tax due to higher expenses. The US market, including Taro Pharmaceuticals, faces challenges, while the global specialty business is expected to grow 14-15%. The Indian market is anticipated to show robust growth of 9-12%. R&D spending is estimated to increase to 6.50% of sales, and EBITDA margins are expected to face pressure due to increased spending on new drug launches.

23Oct 25

Sun Pharmaceutical Industries Sees Rs. 21.42 Crore Block Trade on NSE

Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved approximately 125,307 shares, valued at Rs. 21.42 crores, with a price per share of Rs. 1,709.50. This large-scale trade indicates substantial interest in Sun Pharma's shares and provides insight into the market's current valuation of the company.

22Oct 25

Sun Pharma Strengthens North American Leadership with New Corporate Affairs VP

Sun Pharmaceutical Industries Ltd. has appointed Jeremy Allen as the new Vice President of Corporate Affairs for North America. In this role, Allen will oversee corporate affairs initiatives including government relations, public policy, corporate communications, and stakeholder engagement. This strategic move aims to strengthen Sun Pharma's presence in the North American pharmaceutical market, enhance its ability to navigate regional regulatory environments, and improve stakeholder relations.

08Oct 25

NCLT Approves Sun Pharma's Merger with Subsidiaries, Enhancing Corporate Structure

Sun Pharmaceutical Industries Limited has obtained approval from the National Company Law Tribunal (NCLT) for a corporate restructuring plan. The approved Composite Scheme of Arrangement includes the merger of Sun Pharmaceutical Medicare Limited and four other wholly-owned subsidiaries with Sun Pharma. Additionally, the scheme involves reclassifying Sun Pharma's General Reserve to Retained Earnings. This merger is expected to simplify the company's corporate structure, potentially improving operational efficiency and streamlining decision-making processes.

26Sept 25

Sun Pharma Faces Potential Impact from Trump's 100% Tariff on Branded Drug Imports

US President Donald Trump announced a 100% tariff on branded and patented drugs imported into the United States, effective October 1. This could affect Sun Pharma's specialty product portfolio, which represents 19.30% of its overall sales. The tariffs include exemptions for companies with existing or under-construction US manufacturing plants. Sun Pharma's management suggests their current US manufacturing capacity is sufficient without additional investment. The company's specialty sales reached $1.20 billion, growing 17%, with Illumya sales increasing 17% to $681.00 million. Despite sector-wide concerns, Sun Pharma's stock closed unchanged at ₹1,625.00 and gained 1.50% over the past month.

18Sept 25

Suven Pharmaceuticals Witnesses Massive Block Trades Worth Rs. 3,278 Crores on NSE

Two significant block trades of Suven Pharmaceuticals shares occurred on the NSE during pre-open session, totaling approximately Rs. 3,278.00 crores. The first trade involved 8,712,631 shares worth Rs. 841.95 crores, while the second comprised 25,207,670 shares valued at Rs. 2,435.94 crores. Both trades were executed at Rs. 966.35 per share, involving a total of about 33.92 million shares.

09Sept 25

Sun Pharma's Halol Facility Hit by US FDA Import Alert, Impacting US Market Access

Sun Pharmaceutical Industries Limited's Halol facility has been classified as 'Official Action Indicated' by the U.S. FDA following an inspection from June 2 to June 13. The FDA has placed an import alert on the facility, restricting its ability to ship products to the United States due to non-compliance with current good manufacturing practices. Sun Pharma remains committed to addressing the compliance issues and working with the FDA to maintain CGMP standards at all its facilities.

08Sept 25

Sun Pharma Halts Production of Vecuronium Bromide Injection

Sun Pharmaceutical Industries Limited has stopped manufacturing Vecuronium Bromide Injection 20 MG, a neuromuscular blocking agent used in general anesthesia. The U.S. FDA has officially acknowledged this discontinuation. This decision may impact healthcare providers who regularly use this medication, potentially requiring them to seek alternative suppliers or consider other neuromuscular blocking agents. Sun Pharma has not provided specific reasons for the discontinuation or announced any plans to replace the product.

08Sept 25

Suven Pharmaceuticals Executes Rs. 76.37 Crore Block Trade on NSE

Sun Pharmaceutical Ltd. conducted a significant block trade on the National Stock Exchange (NSE), involving 819,263 shares at Rs. 932.15 per share, totaling Rs. 76.37 crores. This large-scale transaction indicates potential shifts in institutional holdings or strategic moves by major investors, potentially impacting the stock's liquidity and price dynamics in the short term.

05Sept 25

Sun Pharmaceutical Industries Sees Rs. 40.62 Crore Block Trade on NSE

Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved 255,995 shares at Rs. 1,586.70 per share, totaling Rs. 40.62 crore. This large, privately negotiated trade outside regular trading systems may indicate institutional interest or shifts in major shareholding patterns.

01Sept 25

Sun Pharmaceutical Industries Executes Rs. 980 Crore Block Trade on NSE

Sun Pharmaceutical Industries executed a significant block trade on the National Stock Exchange (NSE). The transaction involved 6,227,856 shares traded at Rs. 1,573.60 per share, totaling Rs. 980.02 crores. This large-scale trade indicates potential institutional interest and may impact the company's shareholding patterns and stock liquidity.

04Aug 25

Sun Pharma Promoter Pledges Additional Shares for Third-Party Loan

Raksha Sudhir Valia, associated with Sun Pharmaceutical Industries Limited's promoter group, has pledged 650,000 additional equity shares to Citicorp Finance (India) Limited. This increases her total encumbered shareholding to 12,640,000 shares (0.53% of Sun Pharma's total share capital). The pledge, made on July 28, serves as security for a third-party loan. Valia's total shareholding in Sun Pharma stands at 28,830,352 shares (1.20% of total share capital).

01Aug 25

Sun Pharma Reports Strong Q1 Results Amid US Drug Pricing Pressure

Sun Pharmaceutical Industries Limited reported robust Q1 financial results with consolidated gross sales reaching ₹137,861.00 million, up 10.1% year-over-year. Adjusted net profit rose 5.7% to ₹29,961.00 million. India sales grew 13.9%, while US formulation sales increased 1.4%. The Global Innovative Medicines segment showed impressive 16.9% growth. However, the company faces challenges in the US market due to potential drug pricing pressures.

01Aug 25

Sun Pharma Launches UNLOXCYT for Advanced Skin Cancer Treatment in US Market

Sun Pharma has successfully launched UNLOXCYT (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma treatment in the US market, achieving a significant milestone ahead of original timeline. The treatment shows strong clinical efficacy with 71% disease control rate and manageable safety profile, supported by the company's robust Q1 financial performance of ₹137,861 million gross sales and 10.1% year-over-year growth.

01Aug 25

Sun Pharma Reports Strong Q1 FY26 Performance with 10.1% Revenue Growth, Launches Leqselvi in US

Sun Pharmaceutical Industries Limited reported robust Q1 FY26 results with gross sales reaching ₹137,861.00 million, a 10.1% YoY increase. Adjusted net profit rose 5.7% to ₹29,961.00 million. India formulations sales grew 13.9%, US formulations by 1.4%, and Global Innovative Medicines business by 16.9%. The company launched Leqselvi in the US for severe alopecia areata. R&D investment was ₹9,029.00 million (6.5% of sales). A leadership transition was announced with Kirti Ganorkar set to become the new Managing Director.

01Aug 25

Sun Pharma Reports Strong Q1FY26 Results with 10.1% Revenue Growth

Sun Pharmaceutical Industries Limited reported robust financial results for Q1FY26. Gross sales reached ₹137,861.00 million, up 10.1% year-over-year. Adjusted net profit increased by 5.7% to ₹29,961.00 million, while EBITDA rose 19.2% to ₹43,017.00 million. The company showed strong performance across key markets, with India formulations growing 13.9%, US formulations up 1.4%, and Global Innovative Medicines segment growing 16.9%. Sun Pharma maintained its No. 1 ranking in the Indian pharmaceutical market with an 8.3% market share. R&D investments stood at ₹9,029.00 million, representing 6.5% of sales. The company's pipeline includes 542 approved ANDAs and 119 pending approval in the US market.

31Jul 25

Sun Pharma Reports Strong Q1 FY26 Growth, Reaffirms U.S. Market Commitment

Sun Pharmaceutical Industries Limited reported robust Q1 FY26 results with consolidated gross sales reaching ₹137,861.00 million, a 10.1% year-over-year growth. Adjusted net profit rose by 5.7% to ₹29,961.00 million. EBITDA increased by 19.2% to ₹43,017.00 million. The company maintained leadership in the Indian market, increasing market share to 8.3%. R&D investments were ₹9,029.00 million, representing 6.5% of sales. Sun Pharma launched LEQSELVI in the U.S. market for severe alopecia areata treatment. The company clarified it has no immediate plans to expand manufacturing operations in the U.S.

31Jul 25

Sun Pharma Reports 10.1% Revenue Growth in Q1FY26, Board Approves Committee Restructuring

Sun Pharmaceutical Industries Limited reported robust Q1FY26 results with consolidated gross sales of Rs. 137,861.00 million, up 10.1%. Adjusted net profit increased by 5.7% to Rs. 29,961.00 million. The company maintained its leadership in the Indian market with a 13.9% growth in formulation sales. US formulation sales grew by 1.4%, while global innovative medicines sales increased by 16.9%. The company faced exceptional charges of Rs. 8,180.00 million and announced board restructuring. Sun Pharma also launched the dermatology drug LEQSELVI in the US market.

21Jul 25

Sun Pharma's Tildrakizumab Achieves Primary Endpoint in Phase 3 Psoriatic Arthritis Trials

Sun Pharmaceutical Industries Limited announced successful Phase 3 clinical trials for Tildrakizumab 100 mg (ILUMYA®) in treating active psoriatic arthritis. The INSPIRE-1 and INSPIRE-2 studies met their primary endpoint, showing statistically significant improvement in ACR20 response rates at Week 24 compared to placebo. The trials involved over 800 adult patients across the US, Europe, and Asia. The safety profile was consistent with ILUMYA's known profile, with no new safety signals. Sun Pharma plans to use these results for potential regulatory submissions in the US for ILUMYA in treating active psoriatic arthritis.

17Jul 25

Sun Pharma Expands into China with New Subsidiary

Sun Pharmaceutical Industries Limited has established a new subsidiary, Sun Pharma (Hainan) Company Limited, in China. The subsidiary, registered on July 16, 2025, aims to localize products, collaborate with Chinese partners for production, and conduct sales in the Chinese market. Sun Pharma will maintain 100% ownership of the subsidiary, either directly or through existing subsidiaries. This move provides direct access to the Chinese pharmaceutical market, potentially reducing costs and improving regulatory compliance.

15Jul 25

Sun Pharma Launches LEQSELVI™ in US for Severe Alopecia Areata and Settles Litigation with Incyte

Sun Pharmaceutical Industries Limited has launched LEQSELVI™ (deuruxolitinib) in the United States for treating adults with severe alopecia areata. The company also reached a settlement with Incyte Corporation, resolving litigation related to LEQSELVI™. The agreement includes a limited, non-exclusive license for Sun Pharma and involves upfront and ongoing royalty payments to Incyte. LEQSELVI™, an oral JAK1 and JAK2 inhibitor, showed significant efficacy in clinical trials, with some patients achieving 80% scalp coverage in as fast as 8 weeks. Sun Pharma has introduced a patient support program offering eligible patients medication for as little as $0 for up to two years.

14Jul 25

Sun Pharma Launches LEQSELVI™ for Severe Alopecia Areata in US, Settles Patent Dispute with Incyte

Sun Pharmaceutical Industries Limited has launched LEQSELVI™ (deuruxolitinib) 8 mg tablets in the US for treating severe alopecia areata in adults. The drug showed rapid results in clinical trials, with some patients achieving significant hair regrowth in as little as 8 weeks. Sun Pharma also announced a settlement with Incyte Corporation regarding LEQSELVI™ litigation, including a limited, non-exclusive license for certain US patents. The company will pay Incyte an upfront amount and ongoing royalties. These developments are expected to strengthen Sun Pharma's position in the US pharmaceutical market, particularly in dermatology.

14Jul 25

Sun Pharma Launches Leqselvi for Severe Alopecia Areata Treatment in U.S.

Sun Pharmaceutical Industries Limited has launched LEQSELVI (deuruxolitinib) in the United States for treating severe alopecia areata in adults. LEQSELVI, an oral JAK1 and JAK2 inhibitor, showed significant efficacy in clinical trials, with one-third of patients regaining almost all hair by Week 24. The drug addresses a condition affecting up to 2.50% of the U.S. and global population. Sun Pharma has introduced the LEQSELVI SUPPORT Program to enhance patient access, offering eligible individuals medication for as little as $0 for up to two years. The company has also reached a settlement with Incyte Corporation regarding patent-related litigation.

14Jul 25

Sun Pharma Reaches Settlement with Incyte Corporation in LEQSELVI™ Litigation

Sun Pharmaceutical Industries Limited has reached a settlement and license agreement with Incyte Corporation regarding the litigation over LEQSELVI™ (deuruxolitinib). The settlement includes dismissal of pending litigation, mutual release of claims, and Incyte granting Sun Pharma a limited, non-exclusive license for oral deuruxolitinib in specific non-hematology-oncology indications, including alopecia areata, in the United States. Sun Pharma will pay Incyte an upfront amount and ongoing royalties until patent expiry. This resolution allows Sun Pharma to potentially expand its presence in the U.S. market for certain deuruxolitinib indications.

25Jun 25

Sun Pharma's Partner Withdraws Skin Cancer Treatment Application in Europe

Sun Pharmaceutical Industries Ltd's partner, Philogen S.P.A., has withdrawn the marketing authorization application for their jointly developed skin cancer drug, Nidlegy™, from the European Medicines Agency (EMA). The withdrawal is due to timing issues with data availability. Philogen intends to resubmit an updated application in the future, indicating ongoing commitment to the drug's development. This temporary setback may delay potential revenue from Nidlegy™ in Europe and require additional studies or data before resubmission.

16Jun 25

Sun Pharma's Halol Facility Faces FDA Scrutiny: 8 Observations Issued

Sun Pharmaceutical Industries Ltd's Halol facility in Gujarat underwent a U.S. FDA inspection from June 2 to June 13, resulting in a Form-483 with eight observations. The Form-483 indicates potential violations of the Food Drug and Cosmetic Act, though it's not a final determination of compliance. Sun Pharma must respond with a corrective action plan. The Halol facility has faced previous regulatory challenges, making this inspection significant for the company's U.S. business prospects. The company's response and ability to address these observations will be crucial for maintaining its position in the U.S. market.

16Jun 25

Sun Pharma's Halol Facility Receives FDA Form 483 with 8 Observations Following GMP Inspection

Sun Pharmaceutical's Halol facility has received a Form 483 from the US FDA, citing 8 observations following a GMP inspection. This comes after a previous warning letter and import alert for the same facility. The Halol plant remains under import alert since its last inspection in May 2022. Sun Pharma is expected to respond with a detailed corrective action plan to address the observations and work towards resolving the ongoing regulatory issues.

14Jun 25

FDA Inspection at Sun Pharma's Halol Plant Yields 8 Observations, Facility Remains Under Import Alert

Sun Pharmaceutical Industries Ltd's Halol facility in Gujarat has received a Form 483 from the US FDA following a GMP inspection from June 2-13. The form outlines eight observations, indicating potential GMP compliance issues. This development is significant as the facility is already under import alert due to a previous warning letter. Sun Pharma is expected to review and address these observations to ensure compliance with FDA standards. The Halol facility is crucial for Sun Pharma's US market supply, making resolution of these regulatory issues essential for the company's operations.

13Jun 25

Sun Pharma Announces Leadership Transition: Kirti Ganorkar Named New Managing Director, Dilip Shanghvi to Become Executive Chairman

Sun Pharmaceutical Industries Ltd has announced the appointment of Kirti Ganorkar as its new Managing Director, effective September 1, 2025, subject to shareholder approval. Ganorkar, who has been with the company since 1996, will oversee all business operations. Concurrently, founder Dilip Shanghvi will transition to the role of Executive Chairman of the Board. This leadership change aims to bring fresh perspectives while retaining experienced guidance in the company's strategic direction.

04Jun 25

Sun Pharma's SCD-044 Phase 2 Trial Falls Short of Primary Endpoint

Sun Pharmaceutical Industries Ltd announced that its Phase 2 clinical trial for SCD-044, a potential new medication, did not achieve its primary endpoint. This setback in the drug development process may impact the company's research and development outlook. Sun Pharma has not provided detailed information about next steps, but typical responses include reassessing the drug's potential, exploring alternative indications, or considering modifications to the compound.

03Jun 25

Sun Pharma Discontinues SCD-044 Drug After Failed Trials in Psoriasis and Atopic Dermatitis

Sun Pharmaceutical Industries Ltd has announced the discontinuation of its experimental drug SCD-044 following unsuccessful Phase 2 clinical trials for psoriasis and atopic dermatitis. The drug failed to meet the primary endpoint of 75% symptom improvement in both trials, involving 263 psoriasis patients and 250 atopic dermatitis patients. This represents a significant setback for Sun Pharma's research and development pipeline, leading to the decision to halt further development of SCD-044.

02Jun 25

Sun Pharma Projects Growth on New Launches Amid Profitability Challenges

Sun Pharmaceutical Industries expects mid-to-high single-digit revenue growth in FY26, driven by new product launches including Leqselvi and Unloxcyt. However, increased marketing expenses for specialty products and higher tax obligations may impact profitability. The company plans to invest 6-8% of sales in R&D. Despite a 19% decline in Q4 FY25 net profit due to higher taxes, revenue grew by 8% in the same quarter.

01Jun 25

Sun Pharma Unveils $100 Million Investment Plan for Specialty Products in FY26

Sun Pharmaceutical Industries plans to invest $100 million in FY26 to commercialize new specialty products, focusing on Unloxcyt and Leqselvi. The company aims for mid-to-high single-digit consolidated topline growth and will allocate 6-8% of sales to R&D. Sun Pharma is acquiring Checkpoint Therapeutics and seeking a partner for MM-II development. These strategic moves are aimed at strengthening its product pipeline and market position in the specialty pharmaceutical sector.

30May 25

Sun Pharma Completes Acquisition of Checkpoint Therapeutics

Sun Pharmaceutical Industries Ltd has successfully acquired Checkpoint Therapeutics, a company focused on developing cancer treatments. This strategic move is expected to expand Sun Pharma's oncology portfolio, enhance its R&D capabilities, and strengthen its position in the global pharmaceutical market. The acquisition could lead to synergies in research, development, and commercialization of cancer treatments. Specific financial details of the deal were not disclosed.

24May 25

Sun Pharma Sets Sights on Mid-to-High Single-Digit Revenue Growth for FY26

Sun Pharmaceutical Industries Ltd has announced its revenue growth target for fiscal year 2026, aiming for a mid-to-high single-digit increase. This projection factors in potential regulatory uncertainties in the crucial U.S. market. The company's strategy suggests a focus on sustainable expansion through diversification, innovation, market expansion, and operational efficiency. This cautious yet optimistic outlook reflects Sun Pharma's pragmatic approach to growth amid complex global pharmaceutical regulations.

23May 25

Sun Pharma Invests $25 Million in Pharmazz Inc, Increasing Stake to 22.7%

Sun Pharmaceutical Industries Ltd has agreed to invest up to $25 million in Pharmazz Inc, increasing its stake to 22.7%. The investment supports the development of two advanced drug candidates for stroke and shock. Sun Pharma gains options for licensing rights in certain markets, aligning with its strategy to expand its portfolio and market presence in specialty areas.

23May 25

Sun Pharma Q4 Profit Dips, Revenue Rises; Announces Dividend

Sun Pharmaceutical Industries Ltd reported mixed Q4 results. Net profit decreased to ₹21.50 billion from ₹26.50 billion year-over-year, falling short of market expectations. Revenue increased to ₹129.59 billion from ₹119.80 billion. The company reported an exceptional item of ₹3.62 billion and improved profit before tax of ₹36.20 billion. The board recommended a final dividend of ₹5.50 per equity share.

21May 25

Sun Pharma Q4 Preview: Revenue Growth Expected at 12.9%, Driven by gRevlimid Sales

Sun Pharmaceutical Industries Ltd is set to announce its Q4 results on Thursday. Analysts project a 12.9% YoY revenue increase to Rs 13,254.38 crore, driven by gRevlimid sales. Net profit is expected to rise 5.24% YoY to Rs 2,793.94 crore. US market revenues are anticipated to grow 10% YoY, with healthy growth in India and emerging markets. Investors will focus on R&D guidance, acquisition updates, and plant resolution progress.

20May 25

Sun Pharma Acquires Checkpoint Therapeutics for $616 Million, Bolstering Dermatology-Oncology Portfolio

Sun Pharmaceutical Industries has acquired Checkpoint Therapeutics for $616 million, including a $355 million upfront payment, $60 million contingent payment, and additional royalties. The acquisition, aimed at strengthening Sun Pharma's dermatology-oncology market position, brings key asset Unloxcyt to their portfolio. Macquarie views the deal as value accretive and has raised Sun Pharma's target price to Rs 2,135.00.

19May 25

Sun Pharma's BLU-U Device Upgrade Receives FDA Approval for Skin Treatment

Sun Pharmaceutical Industries has received FDA approval for an upgraded version of its BLU-U Blue Light Photodynamic Therapy device. The new model transitions from fluorescent tubes to LED technology, offering improved efficiency and usability in treating actinic keratosis, a pre-cancerous skin condition. This approval marks a significant advancement in Sun Pharma's medical device portfolio and reinforces its position in dermatological treatments.

16May 25

Sun Pharma's New Photodynamic Therapy Device Receives FDA Approval

Sun Pharmaceutical Industries Ltd. has received FDA approval for its next-generation Blu-U® Blue Light Photodynamic Therapy Illuminator, designed to treat actinic keratosis, a pre-cancerous skin condition. This approval enhances Sun Pharma's dermatology portfolio and reinforces its position in the global dermatology market. The device uses photodynamic therapy for treating pre-cancerous skin lesions, potentially improving patient care and treatment outcomes.

06May 25

Sun Pharma Appoints Jayashree Satagopan as New Chief Financial Officer

Sun Pharmaceutical Industries Ltd. has named Jayashree Satagopan as its new Chief Financial Officer. Satagopan will oversee financial operations, develop strategies, ensure regulatory compliance, and support growth initiatives for the leading Indian pharmaceutical company. This appointment marks a significant change in Sun Pharma's top management, potentially influencing the company's financial direction and performance in the competitive pharmaceutical industry.

24Apr 25

Sun Pharma and Moebius Medical Unveil Promising Results for Novel Osteoarthritis Treatment

Sun Pharmaceutical Industries and Moebius Medical have published two groundbreaking articles in Osteoarthritis and Cartilage journal, showcasing the potential of their novel osteoarthritis treatment, MM-II. A Phase 2b trial demonstrated that a single MM-II injection provided pain relief for up to 26 weeks in knee osteoarthritis patients. The treatment's unique mechanism forms a lubricative layer over cartilage surfaces, potentially reducing friction and slowing cartilage degeneration. MM-II has received Fast Track Designation from the FDA, and new data will be presented at OARSI 2025. The global market for knee osteoarthritis pain relief products is estimated at $2 billion with a 6.5% CAGR.

22Apr 25

Sun Pharma Shares Witness Significant Block Trade on NSE

Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE), involving 90,708 shares valued at Rs. 15.81 crores. The trade was executed at Rs. 1,742.80 per share, representing a substantial portion of the day's trading volume. This transaction highlights ongoing interest in Sun Pharma's stock among large investors.

16Apr 25

Sun Pharma Sees Significant Block Trade on NSE

Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved 125,345 shares traded at Rs. 1,688.90 per share, totaling Rs. 21.17 crores. This large-scale trade has drawn attention from market observers and investors, potentially influencing market sentiment and stock price movements.

11Apr 25

Sun Pharma Wins Court Ruling, Clears Path for LEQSELVI Launch in U.S.

Sun Pharmaceutical Industries Ltd has secured a favorable ruling from the U.S. Court of Appeals, vacating a preliminary injunction that previously blocked the launch of its autoimmune disorder drug, LEQSELVI (deuruxolitinib), in the United States. The drug targets patchy hair loss. While litigation with Incyte Corporation continues, Sun Pharma is no longer restricted from launching LEQSELVI. The company will announce its launch plans for the drug in due course.

10Apr 25

Sun Pharma Wins US Court Appeal, Clears Path for LEQSELVI Launch

Sun Pharmaceutical Industries Ltd has secured a significant legal victory in the United States. The U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction, allowing Sun Pharma to proceed with the launch of LEQSELVI™ (deuruxolitinib), its autoimmune-related hair loss drug. This decision, made on April 9, 2025, overturns a previous ruling by the U.S. District Court for the District of New Jersey. While litigation with Incyte Corporation continues, Sun Pharma is no longer restricted from launching LEQSELVI™ and will announce its launch plans in due course.

10Apr 25

Sun Pharma's Leqselvi Gets Green Light as US Court Vacates Injunction

Sun Pharmaceutical Industries Ltd has secured a significant legal victory in the United States. The U.S. Court of Appeals for the Federal Circuit vacated a preliminary injunction on April 9, 2025, allowing Sun Pharma to proceed with the launch of Leqselvi (deuruxolitinib), a treatment for severe alopecia areata. While litigation with Incyte Corporation continues, Sun Pharma is no longer restricted from launching the medication and will announce its launch plans soon.

07Apr 25

Sun Pharma Launches Fexuclue: A Novel Treatment for Erosive Esophagitis in India

Sun Pharmaceutical Industries Limited has introduced Fexuclue® (Fexuprazan), a novel potassium-competitive acid blocker (P-CAB) for treating Erosive Esophagitis in adults. The medication offers fast-acting, flexible dosing and long-lasting effects. A Phase 3 study showed over 95% efficacy in healing Erosive Esophagitis by 8 weeks. This launch addresses an unmet need in India, where GERD prevalence ranges from 7.60% to 30.00%. The product results from a collaboration with Daewoong Pharmaceutical Co Ltd.

01Apr 25

Sun Pharma Advanced Research Submits IND Application for Cancer Drug SBO-154 to FDA

Sun Pharma Advanced Research Company (SPARC) has submitted an Investigational New Drug (IND) application for SBO-154, a novel compound targeting advanced solid tumors, to the U.S. FDA. This submission paves the way for global Phase 1 clinical trials, potentially leading to new treatment options for cancer patients. The move underscores SPARC's commitment to oncology innovation and could strengthen its position in cancer drug development.

18Mar 25

Sun Pharma Completes CAD 4.5 Million Acquisition of Antibe Therapeutics

Sun Pharmaceutical Industries Limited has finalized its acquisition of Canadian firm Antibe Therapeutics Inc. through its subsidiary TARO Pharmaceuticals Inc. The deal, valued at CAD 4.5 million (approx. ₹27.45 crore), was completed on March 18, 2025. This strategic move aims to expand Sun Pharma's product portfolio and strengthen its presence in the North American market.

11Mar 25

Sun Pharma Acquires Checkpoint Therapeutics in $450 Million Deal to Boost Specialty Business

Sun Pharmaceutical Industries Ltd has agreed to acquire Checkpoint Therapeutics, Inc. for approximately $450 million. The deal, set to close in the second half of 2025, involves a cash payment of $4.10 per share plus potential contingent value rights of up to $0.70 per share. This acquisition aims to strengthen Sun Pharma's specialty business, particularly in dermatology, ophthalmology, and oncology. The key asset is cosibelimab, an anti-PD-L1 antibody in development for treating advanced cutaneous squamous cell carcinoma. The acquisition is expected to be earnings accretive within the first full year after closing.